Summary

Contingent value rights (CVRs) — conditional payments tied to regulatory approval, reimbursement milestones, or sales thresholds — have become standard practice in pharma and biotech acquisitions, with their use rising substantially in recent years. CVRs allow buyers to pay less upfront while promising sellers additional payouts if specified conditions are met. Their growing prevalence reflects a structural problem: market access outcomes remain too uncertain to price at signing. When that uncertainty is large enough to require a deferred payment mechanism, it is market access risk expressed as a contract clause.

Access Impact

CVRs exist because deal parties cannot independently validate the probability of regulatory clearance, payer adoption, or reimbursement success in the target markets. Without a shared reference point — calibrated to how comparable assets have performed at HTA — each party builds its own assumptions into the milestone structure. That asymmetry persists after close. The acquirer controls the pace of development, the evidence strategy, and the commercialization decisions that determine whether milestones are reached. When those incentives diverge from the seller’s expectations, disputes follow. Sanofi paid $315 million to former shareholders of Genzyme to settle claims that it had deliberately slowed development of the multiple sclerosis drug Lemtrada to avoid a contractual CVR payout. The case is the most public example of a broader dynamic: unresolved market access uncertainty, embedded in a contract clause, generating adversarial behavior years after the deal closes. A calibrated, pre-deal assessment of market access probability — anchored to historical HTA and reimbursement outcomes — does not eliminate milestone structures, but it provides both parties with a defensible baseline for the terms they agree to.

Evidence Quality and Robustness

CVR milestones tied to regulatory approval depend on the completeness of the underlying evidence package. Assets with surrogate endpoints, short follow-up, or absent head-to-head comparator data face higher approval uncertainty — which translates directly into higher CVR risk for sellers who negotiated milestones on the assumption of a clean submission.

Cost-Effectiveness

CVR thresholds linked to payer adoption or formulary access reflect implicit assumptions about the asset’s cost-effectiveness profile. Without an independent estimate of how that profile compares to payer thresholds in each target market, milestone terms are set against internal projections — not evidence.

Budget Impact and Resources

Sales-based CVR thresholds — common in oncology and rare disease — depend on payers’ willingness to fund the therapy at meaningful volume. Budget impact tolerance varies significantly by market and therapeutic area. Without a market-level estimate at deal signing, high sales milestones may be structurally unlikely from day one.

Risk Signal

A CVR is not a solution to market access risk. It is a record of how much of that risk remained unresolved at signing. When milestone structures fail — through dispute, litigation, or quiet abandonment — the access problem was typically visible in the evidence package long before the deal closed. The question is whether it was assessed.

#MarketAccess #HTA #MARArating #PharmaMandA

Learn more about Market Access Pharma: https://mararating.com/market-access-pharma/ Source: https://www.biopharmadive.com/news/cvr-biotech-pharma-deals-contingent-value-right-price-acquisitions/806612/